Botanical species · safety record

Piper retrofractum

The EFSA Compendium of Botanicals holds 10 constituent measurements and 3 adverse-effect records for Piper retrofractum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Piper retrofractum Vahl

10Constituent measurements
3Safety records
7Cited sources
3Licensed products (Canada)

Also recorded as

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 3 licensed products naming Piper retrofractum as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry

Source material stated

  • Seed
  • Stem

What the records describe

Constituents measured

  • Lignans3
  • Piperidine alkaloids2
  • Piperine2
  • Alkaloids1
  • Myrcene1
  • Piperlonguminine1

Plant parts

  • Fruit unspecified8
  • Roots and other underground parts2
  • Stem2
  • stalk2
  • Leaves1

Preparations

  • Solvent extraction12
  • Drying (dehydration)1

Effect types

  • Nephrotoxicity1
  • Other toxicities1
  • Pulmonary and cardiac1

Target tissues

  • Heart1
  • Urogenital: kidneys1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
AlkaloidsFruit unspecifiedSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
LignansStem / stalkSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
MyrceneLeavesDrying (dehydration)14.4 PercentGC-MSResolve DOI
Piperidine alkaloidsRoots and other underground partsSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
Piperidine alkaloidsStem / stalkSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
PiperineFruit unspecifiedSolvent extraction31.08 Milligram/gramStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
PiperineRoots and other underground partsSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
PiperlonguminineFruit unspecifiedSolvent extraction1.93 Milligram/gramStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
LignansFruit unspecifiedSolvent extractionGelpermeation, High Performance Thin Layer Chromatography (HPTLC)No resolvable identifier
LignansFruit unspecifiedSolvent extractionGelpermeation, High Performance Thin Layer Chromatography (HPTLC)No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
NephrotoxicityUrogenital: kidneysFruit unspecifiedSolvent extractionRat (as animal)SubchronicNo resolvable identifier
Other toxicitiesFruit unspecifiedSolvent extractionRat (as animal)SubchronicNo resolvable identifier
Pulmonary and cardiacHeartFruit unspecifiedSolvent extractionRat (as animal)SubchronicNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Bao, Narisu., Ochir, Sarangowa., Sun, Zhaorigetu., Borjihan, Gereltu., Yamagishi, Takashi. Occurrence of piperidine alkaloids in Piper species collected in different areas. JOURNAL OF NATURAL MEDICINES, 2014, vol. 68, no. 1, p. 211-214. DOI
  2. Jaijoy, K., Vannasiri, S., Piyabhan, P., Lerdvuthisopon, N., Boonraeng, S., Khonsung, P., Lertprasertsuke, N., Sireeratawong, S. Acute and subchronic toxicity study of the water extract from the fruits of Piper chaba hunter in rats. International Journal of Applied Research in Natural Products, 2010, vol. 3, no. 4, p. 29-35.
  3. Kubo, Miwa., Ishii, Rina., Ishino, Yoichi., Harada, Kenichi., Matsui, Nobuaki., Akagi, Masaaki., Kato, Eishin., Hosoda, Shinya., Fukuyama, Yoshiyasu. Evaluation of Constituents of Piper retrofractum Fruits on Neurotrophic Activity. JOURNAL OF NATURAL PRODUCTS, 2013, vol. 76, no. 4, p. 769-773. DOI
  4. Bodiwala, Hardik S., Singh, Gaganmeet., Singh, Ranvir., Dey, Chinmoy Sankar., Sharma, Shyam Sundar., Bhutani, Kamlesh Kumar., Singh, Inder Pal. Antileishmanial amides and lignans from Piper cubeba and Piper retrofractum. JOURNAL OF NATURAL MEDICINES, 2007, vol. 61, no. 4, p. 418-421. DOI
  5. Haribabu, Kothapalli., Ajitha, Makula., Mallavadhani, Uppuluri Venkata. Simultaneous determination of asaranin and sesamin in Piper chaba fruit by using HPTLC-MS method: effect of different extraction methods on the yield of marker compounds. Journal of Analytical Bioanalytical Techniques, 2014, p. 1000199/1-1000199/6.
  6. Hieu, Le D., Thang, Tran D., Hoi, Tran M., Ogunwande, Isiaka A. Chemical Composition of Essential Oils from Four Vietnamese Species of Piper (Piperaceae) . Journal of oleo science, 2014, vol. 63, no. 3, p. 211-217. DOI
  7. Rao, V. Rama Subba., Suresh, G., Babu, K. Suresh., Raju, S. Satyanarayana., Vardhan, M. V. P. S. Vishnu., Ramakrishna, Sistla., Rao, J. Madhusudana. Novel dimeric amide alkaloids from Piper chaba Hunter: isolation, cytotoxic activity, and their biomimetic synthesis . Tetrahedron, 2011, vol. 67, no. 10, p. 1885-1892. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue